EGFR molecular testing in African-American non-small cell lung cancer patients - A review of discrepant data

Translational Lung Cancer Research

Volumn 2, Issue 3, 2013, Pages 251-255

  Clifford, Bradley T ^a   Fu, Pingfu ^a   Pennell, Nathan A ^b   Halmos, Balazs ^c   Leidner, Rom S ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Department of Orthopaedic Surgery   (United States)

Author keywords

African American; Epidermal growth factor receptor (EGFR); Non small cell lung cancer; Simpson's paradox

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

AFRICAN AMERICAN; AMINO ACID SUBSTITUTION; CAUCASIAN; EXON; HUMAN; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; POINT MUTATION; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; REVIEW; SANGER SEQUENCING; SMOKING; TREATMENT RESPONSE; WILD TYPE;

EID: 84942514507     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2013.01.04     Document Type: Review

References (18)

1. Yang SH, Mechanic LE, Yang P, et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005;11:2106-10.
2. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-44.
3. Tsao AS, Tang XM, Sabloff B, et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 2006;1:231-9.
4. Krishnaswamy S, Kanteti R, Duke-Cohan JS, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009;15:5714-23.
5. Leidner RS, Fu P, Clifford B, et al. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol 2009;27:5620-6.
6. Harada T, Lopez-Chavez A, Xi L, et al. Characterization of epidermal growth factor receptor mutations in nonsmall-cell lung cancer patients of African-American ancestry. Oncogene 2011;30:1744-52.
7. Reinersman JM, Johnson ML, Riely GJ, et al. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 2011;6:28-31.
8. Cote ML, Haddad R, Edwards DJ, et al. Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol 2011;6:627-30.
9. Schwartz AG, Swanson GM. Lung carcinoma in African Americans and whites. A population-based study in metropolitan Detroit, Michigan. Cancer 1997;79:45-52.
10. Simpson EH. The Interpretation of Interaction in Contingency Tables. J Roy Stat Soc B 1951;13:238-41.
11. Mittal Y. Homogeneity of subpopulations and Simpson's paradox. J Am Stat Assoc 1991;86:167-72.
12. Fu P, Panneerselvam A, Clifford B, et al. Simpson's paradox-aggregating and partitioning populations in health disparities of lung cancer patients. Stat Methods Med Res 2012. [Epub ahead of print].
13. Bickel PJ, Hammel EA, O'connell JW. Sex bias in graduate admissions: data from berkeley. Science 1975;187:398-404.
14. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009;4:e7887.
15. Via M, Ziv E, Burchard EG. Recent advances of genetic ancestry testing in biomedical research and direct to consumer testing. Clin Genet 2009;76:225-35.
16. Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-47.
17. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
18. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.